ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 839,14
0,08%
DAX
18 726,76
-0,21%
Brent Oil
82,345
-1,42%
Bitcoin
69 749,97
-2,38%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Adagio Therapeutics Inc (ADGI)

  7. Adagio Therapeutics Inc (ADGI) Actualités

ADGI

Adagio Therapeutics (ADGI)

Adagio Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ADGI
DateHeureSourceTitreSymboleSociété
29/06/202313h09Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ADGIAdagio Therapeutics Inc
26/05/202300h44Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ADGIAdagio Therapeutics Inc
12/04/202322h47Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ADGIAdagio Therapeutics Inc
10/04/202322h20Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ADGIAdagio Therapeutics Inc
10/04/202322h11Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ADGIAdagio Therapeutics Inc
10/04/202322h08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ADGIAdagio Therapeutics Inc
31/03/202322h38Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ADGIAdagio Therapeutics Inc
23/03/202321h31Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ADGIAdagio Therapeutics Inc
09/02/202317h48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ADGIAdagio Therapeutics Inc
19/12/202213h00GlobeNewswire Inc.Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopNASDAQ:ADGIAdagio Therapeutics Inc
06/12/202222h01GlobeNewswire Inc.Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical OfficerNASDAQ:ADGIAdagio Therapeutics Inc
29/11/202223h17Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:ADGIAdagio Therapeutics Inc
10/11/202222h32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ADGIAdagio Therapeutics Inc
06/10/202212h07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ADGIAdagio Therapeutics Inc
12/09/202213h15GlobeNewswire Inc.Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsNASDAQ:ADGIAdagio Therapeutics Inc
12/09/202213h00GlobeNewswire Inc.Adagio Therapeutics Announces Corporate Name Change to InvivydNASDAQ:ADGIAdagio Therapeutics Inc
06/09/202222h01GlobeNewswire Inc.Adagio Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:ADGIAdagio Therapeutics Inc
19/08/202223h23Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ADGIAdagio Therapeutics Inc
15/08/202212h30GlobeNewswire Inc.Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsNASDAQ:ADGIAdagio Therapeutics Inc
05/07/202214h00Business WireMithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy CampaignNASDAQ:ADGIAdagio Therapeutics Inc
05/07/202213h25GlobeNewswire Inc.Adagio Announces David Hering Named Permanent Chief Executive Officer and DirectorNASDAQ:ADGIAdagio Therapeutics Inc
01/07/202212h30GlobeNewswire Inc.Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of DirectorsNASDAQ:ADGIAdagio Therapeutics Inc
06/06/202212h03Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:ADGIAdagio Therapeutics Inc
02/06/202222h25Edgar (US Regulatory)Information Statement - Contested Solicitations (definitive) (defc14c)NASDAQ:ADGIAdagio Therapeutics Inc
19/05/202223h07Edgar (US Regulatory)Information Statement - Contested Solicitations (preliminary) (prec14c)NASDAQ:ADGIAdagio Therapeutics Inc
19/05/202222h31ValueWalkAdagio Therapeutics Jumps 629 Ranks To 119th Most Owned Stock On The PlatformNASDAQ:ADGIAdagio Therapeutics Inc
17/05/202214h45TipRanksAdagio Therapeutics (ADGI) Gets a Sell Rating from Morgan StanleyNASDAQ:ADGIAdagio Therapeutics Inc
13/05/202216h26Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ADGIAdagio Therapeutics Inc
13/05/202212h30GlobeNewswire Inc.Adagio Therapeutics Reports First Quarter 2022 Financial ResultsNASDAQ:ADGIAdagio Therapeutics Inc
29/04/202223h22Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ADGIAdagio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ADGI

Dernières Valeurs Consultées

NYSE
MRK
Merck
EU
LR
Legrand
EU
ACA
Credit Agricole
EU
SGO
Cie de SaintGobain
NASDAQ
AMZN
Amazon.com
EU
ML
Michelin
EU
PX4
SBF 120
EU
GLE
Societe Generale
NYSE
NKE
Nike
EU
PX1
CAC 40
EU
VK
Vallourec
NYSE
KO
Coca Cola
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés